Skip to main content

Advertisement

Table 2 Response to HCV therapy

From: German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients

Response to HCV therapy Group A: HCV/HIV co-infected patients Group B: HCV mono-infected patients p-values
SVR all, n (%) 18/36 (50) 27/52 (52) 0.860
RVR, n (%) 9/36 (25) 17/52 (32) 0.440
EVR, n (%) 6/36 (17) 7/52 (13) 0.677
 SVR GT 1, n (%) 5/15 (33) 11/27 (40) 0.626
 SVR GT 2, n (%) 1/2 (50) 7/8 (87) 0.356
 SVR GT 3, n (%) 9/14 (64) 7/12 (58) 0.756
 SVR GT 4, n (%) 1/1 (100) 2/4 (50) 0.600
 GT unknown, n (%) 2/36 (5) 0/52 (0) 0.809
 SVR GT 1 + 4, n (%) 6/16 (37) 13/31 (41) 0.770
 SVR GT 2 + 3, n (%) 10/16 (62) 14/20 (70) 0.636
Discontinuation of therapy, n (%) 3/36 (12) 4/52 (7) 0.305
Breakthrough infection, n (%) 1/36 (2) 0/52 0.410
Non-response, n (%) 5/36 (13) 3/52 (5) 0.130
Relapse, n (%) 7/36 (19) 9/52 (17) 0.482
Unknown, n (%) 2/36 (5) 9/52 (17) 0.105
SVR HAART treated patients, n (%) 14/29 (48) n.a. n.a.
SVR non-HAART treated patients, n (%) 4/7 (57) n.a. n.a.
SVR CD4 Nadir > 200/μl, n (%) 9/18 (50) n.a. n.a.
SVR CD4 Nadir < 200/μl, n (%) 9/18 (50) n.a. n.a.